Recent chatter on X about DiaMedica Therapeutics (DMAC) has centered on the company’s announcement of a $30.1 million private placement, a move that has sparked considerable interest among investors. Many users are discussing how this capital raise could fuel the acceleration of their pipeline, particularly for treatments targeting preeclampsia and fetal growth restriction. The news of insider purchases at $3.50 per share has also caught attention, with some interpreting it as a strong signal of confidence in the company’s future.
Additionally, posts on X have highlighted the positive interim results from a Phase 2 trial for DM199, DiaMedica’s lead drug candidate for preeclampsia, with some expressing optimism about its potential impact on the stock’s trajectory. Discussions also touch on analyst price targets, with a few noting a recent hike to $12 by a major firm, fueling speculation about future gains. The tone across these conversations suggests a growing curiosity about whether DiaMedica can deliver on its clinical promises.
Note: This discussion summary was generated from an AI condensation of post data.
DiaMedica Therapeutics Insider Trading Activity
DiaMedica Therapeutics insiders have traded $DMAC stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $DMAC stock by insiders over the last 6 months:
- KOCH THOMAS VON purchased 2,857,142 shares for an estimated $9,999,997
- JAN STAHLBERG purchased 1,542,857 shares for an estimated $5,399,999
- RICHARD II JACINTO purchased 400,000 shares for an estimated $1,400,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DiaMedica Therapeutics Hedge Fund Activity
We have seen 35 institutional investors add shares of DiaMedica Therapeutics stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 252,051 shares (+297.1%) to their portfolio in Q1 2025, for an estimated $955,273
- FIRST MANHATTAN CO. LLC. removed 232,646 shares (-27.7%) from their portfolio in Q1 2025, for an estimated $881,728
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 181,748 shares (+48.5%) to their portfolio in Q1 2025, for an estimated $688,824
- ROYAL BANK OF CANADA added 154,701 shares (+46879.1%) to their portfolio in Q1 2025, for an estimated $586,316
- VANGUARD GROUP INC added 109,360 shares (+8.8%) to their portfolio in Q1 2025, for an estimated $414,474
- PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE added 85,216 shares (+16.6%) to their portfolio in Q1 2025, for an estimated $322,968
- 683 CAPITAL MANAGEMENT, LLC removed 76,116 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $288,479
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DiaMedica Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $DMAC in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/18/2025
- Craig-Hallum issued a "Buy" rating on 07/18/2025
- Lake Street issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for DiaMedica Therapeutics, check out Quiver Quantitative's $DMAC forecast page.
DiaMedica Therapeutics Price Targets
Multiple analysts have issued price targets for $DMAC recently. We have seen 3 analysts offer price targets for $DMAC in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $12.0 on 07/18/2025
- Chase Knickerbocker from Craig-Hallum set a target price of $11.0 on 07/18/2025
- Thomas Flaten from Lake Street set a target price of $14.0 on 07/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
